Please fax both pages of completed form to your team at 888.302.1028.

To reach your team, call toll-free 844.516.3319.

You can now monitor shipments and chat online if you have questions. Go to MyAccredoPatients.com to log in or get started.

Prescription & Enrollment Form

Multiple Sclerosis (E–M)



Four simple steps to submit your referral.

1 Patient Infor	mation		Please attach copion in prescription in	es of front and back of the p surance cards.	patient's medical
☐ New patient ☐ Current pat	ient				
Patient's first name		Las	t name		Middle initial
☐ Male ☐ Female Last 4 d	igits of SSN		D	ate of birth	
Street address					
City					
Home phone					
Parent/guardian (if applicable)					
Home phone					
Alternate caregiver/contact Home phone					
□ OK to leave message with all			E-IIIali au	uress	
Patient's primary language:	•	nlease specify			
2 Prescriber In				completed to expedite presc	
Date				d	
Prescriber's first name					
Prescriber's title		If N	P or PA, under dire	ection of Dr	
Office address					
Office contact and title					
Office contact phone number _		Office co	ntact e-mail		
Office/Infusion clinic name		Offic	e/Infusion clinic aft	filiation	
Street address					Suite #
City		State		Zip	
Phone					
3 Clinical Infor					
Primary ICD-10 code:		_ Laboratory re	esults: LEVF		Date
Platelets	Date _		ANC		Date
Pregnancy test	(+/-) Date	Bilirubin	mg/dL	Patient weight	Date
EXPECTED DATE OF FIRST/NI	EXT INJECTION		DATE OF LAST I	NJECTION (if applicable) _	
Agency nurse to visit home for	injection: 🗆 Yes 🗅 No 🛛 A	gency name &	ohone		
□ NKDA □ Known drug allergi	es				
Concurrent meds					

Patient's first name	Last name	Middle initial	Date of birth
Prescriber's first name	Last name		Phone
4 Prescribing Information			

Medication	Strength/Formu	lation	Directions						Qı	Quantity/Refills				
□ Extavia® (interferon beta-1b)	0.3mg vial		☐ Inject 0.25mg (1mL) subcutaneously every other day. ☐ Dose Titration: • Weeks 1–2: Inject 0.0625mg/0.25mL subcutaneously every other day • Weeks 3–4: Inject 0.125mg/0.50mL subcutaneously every other day • Weeks 5–6: Inject 0.1875mg/0.75mL subcutaneously every other day • Weeks 7+: Inject 0.25mg/ 1mL subcutaneously every other day						y Re	□ 30-day supply (1 kit) □ 90-day supply (3 kits) Refills				
□ Gilenya [®] (fingolimod)	0.5mg capsule	Take one 0.5mg capsule by mouth once daily.								□ 30-day supply #30 □ 90-day supply #90 Refills				
☐ Kesimpta® (ofatumumab)	20mg (0.4mL)	 □ Loading dose: Inject 1 unit (0.4mL) subcutaneously at week 0, 1 and 2. □ Maintenance dose: Inject 1 unit (0.4mL) each month. 							Supply: 4-week supply 12-week supply Other Refills					
Lemtrada® (alemtuzumab)	Access Lemtrada® referral form on accredo.com.													
☐ Mavenclad® (cladribine)	10mg tablet	Treatment course: ☐ Year 1 ☐ Year 2 ☐ Take daily by mouth at intervals of 24 hours approximately the same time each day. Check the row corresponding to the patient's weight to prescribe the appropriate number of tablets. Tablets should be taken on consecutive days during each treatment week.								fills: None				
	Weight Range (kg)	Number of 10mg tablets per week												
		Day 1	Week 1 Day 1 Day 2 Day 3 Day 4 Day 5 Total Tablets					Day 1	Week 5 Day 1 Day 2 Day 3 Day 4 Day			Day 5	Total Tablets	Total Tablets
	☐ 40 to <50	1	1	1	1	0	Week 1	1	1	1	1	0	Week 5	8 (80mg)
	50 to <60	1	1	1	1	1	5	1	1	1	1	1	5	10 (100mg)
	☐ 60 to <70	2	1	1	1	1	6	2	1	1	1	1	6	12 (120mg)
	☐ 70 to <80	2	2	1	1	1	7	2	2	1	1	1	7	14 (140mg)
	☐ 80 to <90	2	2	2	1	1	8	2	2	1	1	1	7	15 (150mg)
	☐ 90 to <100	2	2	2	2	1	9	2	2	2	1	1	8	17 (170mg)
	☐ 100 to <110	2	2	2	2	2	10	2	2	2	2	1	9	19 (190mg)
	110 and above	2	2	2	2	2	10	2	2	2	2	2	10	20 (200mg)
Other	Other instructions	:											ipply: 30-day 🗖 9 Other efills	

Prescriber's signature (sign below) (Physician attests this is his/her legal signature. NO STAMPS)

Date Dispense as written Date Substitution allowed

The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to the prescriber.



PHYSICIAN SIGNATURE REQUIRED